Neoplasm

6 trials 3 recruiting MedDRA PT
6 Registered trials
3 Recruiting
5 Unique sponsors
1 Unique IMPs
6 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
Mechanism of action (INN-stem analysis)
Antibody-drug conjugate (ADC) 1 substance
Phase III: 1 Phase I: 4 Phase I (Other): 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

1 trial
  • Daiichi Sankyo Inc. Commercial
    TRASTUZUMAB DERUXTECAN
    2023-506330-73-00 4 countries 2024 n=64
    Recruiting

Phase I

4 trials
  • Alterome Therapeutics Inc. Commercial
    IMP not specified
    2024-515391-12-00 2 countries 2025 n=20
    Ended
  • Daiichi Sankyo Inc. Commercial
    IMP not specified
    2023-503965-48-00 3 countries 2024 n=36
    Recruiting
  • Gilead Sciences Inc. Commercial
    IMP not specified
    2025-522397-36-00 1 country 2025 n=35
    Recruiting
  • iTeos Belgium Commercial
    IMP not specified
    2024-520369-30-00 1 country n=47
    Ended

Phase I (Other)

1 trial
  • Navire Pharma Inc. Commercial
    IMP not specified
    2022-501363-40-00 7 countries 2023 n=75
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Daiichi Sankyo Inc. Commercial 2 Phase I, Phase III 2
Alterome Therapeutics Inc. Commercial 1 Phase I 0
Gilead Sciences Inc. Commercial 1 Phase I 1
iTeos Belgium Commercial 1 Phase I 0
Navire Pharma Inc. Commercial 1 Phase I (Other) 0
New trials by year
2023
1
2024
2
2025
2
← All indication landscapes